NASDAQ:INCY - Nasdaq - US45337C1027 - Common Stock - Currency: USD
62.66
+2.23 (+3.69%)
The current stock price of INCY is 62.66 USD. In the past month the price increased by 2.87%. In the past year, price increased by 16.56%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19 | 345.13B | ||
AMGN | AMGEN INC | 14.68 | 156.41B | ||
GILD | GILEAD SCIENCES INC | 13.76 | 132.82B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1756.9 | 130.98B | ||
REGN | REGENERON PHARMACEUTICALS | 13.51 | 65.46B | ||
ARGX | ARGENX SE - ADR | 339.55 | 39.39B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.24B | ||
ONC | BEIGENE LTD-ADR | N/A | 28.00B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.04B | ||
NTRA | NATERA INC | N/A | 20.40B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.79B | ||
BIIB | BIOGEN INC | 7.35 | 17.72B |
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,617 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
INCYTE CORP
1801 Augustine Cut-Off
Wilmington DELAWARE 19803 US
CEO: Herve Hoppenot
Employees: 2524
Company Website: https://www.incyte.com/
Investor Relations: https://investor.incyte.com/
Phone: 13024986700
The current stock price of INCY is 62.66 USD. The price increased by 3.69% in the last trading session.
The exchange symbol of INCYTE CORP is INCY and it is listed on the Nasdaq exchange.
INCY stock is listed on the Nasdaq exchange.
33 analysts have analysed INCY and the average price target is 75.43 USD. This implies a price increase of 20.39% is expected in the next year compared to the current price of 62.66. Check the INCYTE CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
INCYTE CORP (INCY) has a market capitalization of 12.13B USD. This makes INCY a Large Cap stock.
INCYTE CORP (INCY) currently has 2524 employees.
INCYTE CORP (INCY) has a support level at 59 and a resistance level at 62.67. Check the full technical report for a detailed analysis of INCY support and resistance levels.
The Revenue of INCYTE CORP (INCY) is expected to grow by 11.03% in the next year. Check the estimates tab for more information on the INCY EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
INCY does not pay a dividend.
INCYTE CORP (INCY) will report earnings on 2025-07-28, before the market open.
The PE ratio for INCYTE CORP (INCY) is 34.05. This is based on the reported non-GAAP earnings per share of 1.84 and the current share price of 62.66 USD. Check the full fundamental report for a full analysis of the valuation metrics for INCY.
The outstanding short interest for INCYTE CORP (INCY) is 3.93% of its float. Check the ownership tab for more information on the INCY short interest.
ChartMill assigns a technical rating of 2 / 10 to INCY. When comparing the yearly performance of all stocks, INCY turns out to be only a medium performer in the overall market: it outperformed 63.5% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to INCY. While INCY has a great profitability rating, there are some minor concerns on its financial health.
Over the last trailing twelve months INCY reported a non-GAAP Earnings per Share(EPS) of 1.84. The EPS decreased by -51.45% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 0.77% | ||
ROA | 0.6% | ||
ROE | 0.95% | ||
Debt/Equity | 0.01 |
ChartMill assigns a Buy % Consensus number of 74% to INCY. The Buy consensus is the average rating of analysts ratings from 33 analysts.
For the next year, analysts expect an EPS growth of 350.35% and a revenue growth 11.03% for INCY